MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.critrevonc.2026.105661

Медицинская библиотека · Critical reviews in oncology/hematology · 2026

Antibody-drug conjugates after EGFR-TKI resistance in EGFR-mutant NSCLC: Evidence boundaries, post-progression reassessment, and therapeutic sequencing.

Wang Linlin, Feng Yong, Jia Renxiang, Liu Qiang

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Antibody-drug conjugates (ADCs) are emerging therapeutic options for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) after the development of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, the founding EGFR alteration alone does not guide ADC selection. At progression, actionable resistance mechanisms, altered antigen expression, central nervous system (CNS) involvement, spatial heterogeneity, and histological transformation may shift treatment priorities. This narrative review links agent-specific evidence boundaries to an eight-domain assessment of the post-progression disease state and distinguishes ADC eligibility from therapeutic priority. The framework first identifies clinical scenarios requiring immediate local, CNS-directed, or lineage-specific treatment. It then evaluates resistance-directed therapy and other systemic options in the context of prior treatment. Finally, each ADC is assessed according to its evidence base, biomarkers, construct fit, disease distribution, availability, and patient-specific safety. Currently, selected TROP2-directed ADCs have the most mature evidence. HER3-directed therapy remains under investigation, whereas c-Met- and human epidermal growth factor receptor 2-directed ADCs may be relevant in biomarker-defined settings. Tissue biopsy, plasma circulating tumor DNA analysis, and selected cerebrospinal fluid testing should be considered when the findings could alter clinical management. Accordingly, ADCs should be positioned relative to competing local and systemic strategies rather than considered a uniform post-osimertinib class. Prospective validation is required to determine whether this framework improves treatment outcomes.

Для цитирования: Wang Linlin, Feng Yong, Jia Renxiang, Liu Qiang. Antibody-drug conjugates after EGFR-TKI resistance in EGFR-mutant NSCLC: Evidence boundaries, post-progression reassessment, and therapeutic sequencing.. Critical reviews in oncology/hematology. 2026. DOI: 10.1016/j.critrevonc.2026.105661.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.